Evidence map›Paper›PMID 38764379›Full record

ArticleThe American journal of surgical pathology2024

PanIN or IPMN? Redefining Lesion Size in 3 Dimensions.

Ashley L Kiemen, Lucie Dequiedt, Yu Shen, Yutong Zhu, Valentina Matos-Romero, André Forjaz, Kurtis Campbell, Will Dhana, Toby Cornish, Alicia M Braxton and 5 more

Abstract read
In one paragraph

Article in The American journal of surgical pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ashley L KiemenDepartments of Pathology.
Lucie DequiedtDepartment of Comparative Medicine, Medical University of South Carolina, Charleston, SC.
Yu ShenDepartment of Comparative Medicine, Medical University of South Carolina, Charleston, SC.
Yutong ZhuDepartment of Comparative Medicine, Medical University of South Carolina, Charleston, SC.
Valentina Matos-RomeroDepartment of Comparative Medicine, Medical University of South Carolina, Charleston, SC.
André ForjazDepartment of Comparative Medicine, Medical University of South Carolina, Charleston, SC.
Kurtis CampbellDepartments of Pathology.
Will DhanaDepartment of Comparative Medicine, Medical University of South Carolina, Charleston, SC.
Toby CornishDepartment of Comparative Medicine, Medical University of South Carolina, Charleston, SC.
Alicia M BraxtonDepartment of Comparative Medicine, Medical University of South Carolina, Charleston, SC.
Pei-Hsun WuDepartment of Comparative Medicine, Medical University of South Carolina, Charleston, SC.
Elliot K FishmanDepartment of Comparative Medicine, Medical University of South Carolina, Charleston, SC.
Laura D WoodDepartments of Pathology.
Denis WirtzDepartments of Pathology.
Ralph H HrubanDepartments of Pathology.

Funding

Tech Core 2U54CA268083 · NCI · JOHNS HOPKINS UNIVERSITY · PI Pei-Hsun wu · 2022 to 2026
$10.2M
Three-dimensional maps of senescence in the human pancreasUH3CA275681 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, PEI-HSUN · 2024 to 2025
$1.7M
Three-dimensional maps of senescence in the human pancreasUG3CA275681 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, PEI-HSUN · 2022 to 2023
$1.1M
Organ Specific ProjectU54AR081774 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI REDDY, SASHANK K, WIRTZ, DENIS · 2022 to 2023
$1.1M
NCI NIH HHS U54 CA268083NCI NIH HHS UG3 CA275681NCI NIH HHS UH3 CA275681NIAMS NIH HHS U54 AR081774
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) develops from 2 known precursor lesions: a majority (∼85%) develops from pancreatic intraepithelial neoplasia (PanIN), and a minority develops from intraductal papillary mucinous neoplasms (IPMNs). Clinical classification of PanIN and IPMN relies on a combination of low-resolution, 3-dimensional (D) imaging (computed tomography, CT), and high-resolution, 2D imaging (histology). The definitions of PanIN and IPMN currently rely heavily on size. IPMNs are defined as macroscopic: generally >1.0 cm and visible in CT, and PanINs are defined as microscopic: generally <0.5 cm and not identifiable in CT. As 2D evaluation fails to take into account 3D structures, we hypothesized that this classification would fail in evaluation of high-resolution, 3D images. To characterize the size and prevalence of PanINs in 3D, 47 thick slabs of pancreas were harvested from grossly normal areas of pancreatic resections, excluding samples from individuals with a diagnosis of an IPMN. All patients but one underwent preoperative CT scans. Through construction of cellular resolution 3D maps, we identified >1400 ductal precursor lesions that met the 2D histologic size criteria of PanINs. We show that, when 3D space is considered, 25 of these lesions can be digitally sectioned to meet the 2D histologic size criterion of IPMN. Re-evaluation of the preoperative CT images of individuals found to possess these large precursor lesions showed that nearly half are visible on imaging. These findings demonstrate that the clinical classification of PanIN and IPMN fails in evaluation of high-resolution, 3D images, emphasizing the need for re-evaluation of classification guidelines that place significant weight on 2D assessment of 3D structures.

Indexed as

Carcinoma, Pancreatic DuctalImaging, Three-DimensionalPancreatic Intraductal NeoplasmsPancreatic NeoplasmsAgedCarcinoma in SituFemaleHumansMaleMiddle AgedPredictive Value of TestsTomography, X-Ray ComputedTumor Burden

Identifiers

PMID38764379
PMCPMC11189722

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.